Literature DB >> 27254841

What Can Rats Tell Us about Adolescent Cannabis Exposure? Insights from Preclinical Research.

Justine Renard1, Walter J Rushlow2, Steven R Laviolette2.   

Abstract

Marijuana is the most widely used drug of abuse among adolescents. Adolescence is a vulnerable period for brain development, during which time various neurotransmitter systems such as the glutamatergic, GABAergic, dopaminergic, and endocannabinoid systems undergo extensive reorganization to support the maturation of the central nervous system (CNS). ▵-9-tetrahydrocannabinol (THC), the psychoactive component of marijuana, acts as a partial agonist of CB1 cannabinoid receptors (CB1Rs). CB1Rs are abundant in the CNS and are central components of the neurodevelopmental changes that occur during adolescence. Thus, overactivation of CB1Rs by cannabinoid exposure during adolescence has the ability to dramatically alter brain maturation, leading to persistent and enduring changes in adult cerebral function. Increasing preclinical evidence lends support to clinical evidence suggesting that chronic adolescent marijuana exposure may be associated with a higher risk for neuropsychiatric diseases, including schizophrenia. In this review, we present a broad overview of current neurobiological evidence regarding the long-term consequences of adolescent cannabinoid exposure on adult neuropsychiatric-like disorders.
© The Author(s) 2016.

Entities:  

Keywords:  adolescence; cannabinoids; cannabis; dopamine; hippocampus; prefrontal cortex; psychiatric disorders; rodents; schizophrenia; synaptic plasticity; ventral tegmental area

Mesh:

Year:  2016        PMID: 27254841      PMCID: PMC4872245          DOI: 10.1177/0706743716645288

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  54 in total

1.  Chronic THC during adolescence increases the vulnerability to stress-induced relapse to heroin seeking in adult rats.

Authors:  Serena Stopponi; Laura Soverchia; Massimo Ubaldi; Andrea Cippitelli; Giovanni Serpelloni; Roberto Ciccocioppo
Journal:  Eur Neuropsychopharmacol       Date:  2013-12-24       Impact factor: 4.600

2.  Periadolescent exposure to cannabinoids alters the striatal and hippocampal dopaminergic system in the adult rat brain.

Authors:  Alejandro Higuera-Matas; Fanny Botreau; Nuria Del Olmo; Miguel Miguéns; Oscar Olías; Gonzalo L Montoya; Carmen García-Lecumberri; Emilio Ambrosio
Journal:  Eur Neuropsychopharmacol       Date:  2010-07-23       Impact factor: 4.600

3.  Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats.

Authors:  N Realini; D Vigano'; C Guidali; E Zamberletti; T Rubino; D Parolaro
Journal:  Neuropharmacology       Date:  2010-09-17       Impact factor: 5.250

Review 4.  Pharmacology of cannabinoid receptor ligands.

Authors:  R G Pertwee
Journal:  Curr Med Chem       Date:  1999-08       Impact factor: 4.530

5.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.

Authors:  A Breier; T P Su; R Saunders; R E Carson; B S Kolachana; A de Bartolomeis; D R Weinberger; N Weisenfeld; A K Malhotra; W C Eckelman; D Pickar
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

6.  Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment.

Authors:  Nico Wegener; Michael Koch
Journal:  Brain Res       Date:  2008-12-03       Impact factor: 3.252

7.  Chronic periadolescent cannabinoid treatment enhances adult hippocampal PSA-NCAM expression in male Wistar rats but only has marginal effects on anxiety, learning and memory.

Authors:  A Higuera-Matas; F Botreau; M Miguéns; N Del Olmo; E Borcel; L Pérez-Alvarez; C García-Lecumberri; E Ambrosio
Journal:  Pharmacol Biochem Behav       Date:  2009-07-02       Impact factor: 3.533

8.  Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates.

Authors:  Tiziana Rubino; Daniela Vigano'; Natalia Realini; Cinzia Guidali; Daniela Braida; Valeria Capurro; Chiara Castiglioni; Francesca Cherubino; Patrizia Romualdi; Sanzio Candeletti; Mariaelvina Sala; Daniela Parolaro
Journal:  Neuropsychopharmacology       Date:  2008-01-02       Impact factor: 7.853

9.  Augmented acquisition of cocaine self-administration and altered brain glucose metabolism in adult female but not male rats exposed to a cannabinoid agonist during adolescence.

Authors:  Alejandro Higuera-Matas; María Luisa Soto-Montenegro; Nuria del Olmo; Miguel Miguéns; Isabel Torres; Juan José Vaquero; Javier Sánchez; Carmen García-Lecumberri; Manuel Desco; Emilio Ambrosio
Journal:  Neuropsychopharmacology       Date:  2007-06-06       Impact factor: 7.853

Review 10.  Attentional set-shifting in rodents: a review of behavioural methods and pharmacological results.

Authors:  David S Tait; E Alexander Chase; Verity J Brown
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

View more
  12 in total

1.  Effects of Adolescent Cannabinoid Self-Administration in Rats on Addiction-Related Behaviors and Working Memory.

Authors:  Erin K Kirschmann; Michael W Pollock; Vidhya Nagarajan; Mary M Torregrossa
Journal:  Neuropsychopharmacology       Date:  2016-09-01       Impact factor: 7.853

2.  Adolescent cannabinoid exposure effects on natural reward seeking and learning in rats.

Authors:  H Schoch; M Y Huerta; C M Ruiz; M R Farrell; K M Jung; J J Huang; R R Campbell; D Piomelli; S V Mahler
Journal:  Psychopharmacology (Berl)       Date:  2017-10-11       Impact factor: 4.530

3.  Prenatal THC exposure raises kynurenic acid levels in the prefrontal cortex of adult rats.

Authors:  Sarah Beggiato; Alessandro Ieraci; Maria Cristina Tomasini; Robert Schwarcz; Luca Ferraro
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-02-04       Impact factor: 5.067

4.  THC exposure during adolescence does not modify nicotine reinforcing effects and relapse in adult male mice.

Authors:  África Flores; Rafael Maldonado; Fernando Berrendero
Journal:  Psychopharmacology (Berl)       Date:  2019-12-19       Impact factor: 4.530

5.  Adolescent cannabinoid exposure modulates the vulnerability to cocaine-induced conditioned place preference and DNMT3a expression in the prefrontal cortex in Swiss mice.

Authors:  P H Gobira; A L Roncalho; N R Silva; G P Silote; A J Sales; S R Joca
Journal:  Psychopharmacology (Berl)       Date:  2021-07-30       Impact factor: 4.530

Review 6.  Review of the Endocannabinoid System.

Authors:  Hui-Chen Lu; Ken Mackie
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2020-08-01

7.  Consequences of Adolescent Exposure to the Cannabinoid Receptor Agonist WIN55,212-2 on Working Memory in Female Rats.

Authors:  Erin K Kirschmann; Daniel M McCalley; Caitlyn M Edwards; Mary M Torregrossa
Journal:  Front Behav Neurosci       Date:  2017-07-21       Impact factor: 3.558

8.  Adolescent Exposure to the Synthetic Cannabinoid WIN 55212-2 Modifies Cocaine Withdrawal Symptoms in Adult Mice.

Authors:  María A Aguilar; Juan Carlos Ledesma; Marta Rodríguez-Arias; Carles Penalva; Carmen Manzanedo; José Miñarro; M Carmen Arenas
Journal:  Int J Mol Sci       Date:  2017-06-21       Impact factor: 5.923

Review 9.  Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence.

Authors:  Grace Blest-Hopley; Marco Colizzi; Vincent Giampietro; Sagnik Bhattacharyya
Journal:  Front Psychiatry       Date:  2020-08-26       Impact factor: 4.157

10.  Early 5-HT6 receptor blockade prevents symptom onset in a model of adolescent cannabis abuse.

Authors:  Al Mahdy Hamieh; Angelina Rogliardo; Philippe Marin; Carine Bécamel; Coralie Berthoux; Emilie L Doucet; Camille Coudert; Fabrice Ango; Katarzyna Grychowska; Séverine Chaumont-Dubel; Pawel Zajdel; Rafael Maldonado; Joël Bockaert
Journal:  EMBO Mol Med       Date:  2020-04-24       Impact factor: 14.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.